Bausch and Lomb Newswire (Page 8)

Bausch and Lomb Newswire (Page 8)

Comprehensive Real-Time News Feed for Bausch and Lomb. (Page 8)

Results 141 - 160 of 842 in Bausch and Lomb

  1. Why Valeant Pharmaceuticals Stock Is Soaring TodayRead the original story

    May 9, 2017 | Fox News

    As part of its first-quarter earnings report, the drugmaker upped its full-year adjusted EBITDA to between $3.6 and $3.75 billion, compared to its prior guidance of $3.55 to $3.70 billion. The company also lowered its debt load by a hefty $1.3 billion during the three-month period.

    Comment?

  2. B&L parent Valeant sees stock jump after boosting guidanceRead the original story

    May 9, 2017 | Rochester Business Journal

    Bausch & Lomb Inc. parent Valeant Pharmaceuticals International Inc. stock price surged more than 17 percent Tuesday as the company reported a $1 billion improvement in net income for the first quarter and improved it 2017 guidance. The Bausch & Lomb/International segment reported first-quarter revenue of $1.15 billion up less than 1 percent from the same quarter a year ago.

    Comment?

  3. Valeant shares surgeRead the original story w/Photo

    May 9, 2017 | Castanet.net

    Valeant Pharmaceuticals stock jumped Tuesday after the Quebec-based drugmaker reported its first net profit in six quarters, raised its 2017 adjusted earnings forecast and said it made further progress in paying down debt. On the Toronto Stock Exchange, the company's stock gained $2.02 or 15 per cent at C$15.38 in morning trading, well off its 52-week high of $42.25 but the strongest in weeks.

    Comment?

  4. Valeant shares jump as company boosts financial forecast, reduces debtRead the original story w/Photo

    May 9, 2017 | CBC News

    Valeant Pharmaceuticals chief executive Joe Papa speaks to reporters after the company's 2017 annual meeting on May 2 in Laval, Que. Valeant Pharmaceuticals stock jumped Tuesday after the Quebec-based drugmaker reported its first net profit in six quarters, raised its 2017 adjusted earnings forecast and said it made further progress in paying down debt.

    Comment?

  5. Bausch & Lomb Announces PDUFA Date For New OTC Redness Reliever,...Read the original story

    May 8, 2017 | BioSpace

    Luminesse is a topical vasoconstrictor formulation to be used Over-the-Counter as an eye drop to relieve redness of the eye due to minor eye irritations. If approved, this will be the first OTC product developed with brimonidine tartrate for the treatment of ocular redness.

    Comment?

  6. Contact Lens Market: Cast Molding Emerges as Most Sought After Contact Lens Manufacturing TechnologyRead the original story w/Photo

    May 9, 2017 | PR-inside.com

    The global market for contact lenses features a consolidated competitive landscape, with the top four companies, including Johnson & Johnson, The Cooper Companies, Alcona Inc. and Bausch and Lomb, accounting for a share of nearly 68% in the global market in 2015, states Transparency Market Research in a new report. Johnson & Johnson, the largest vendor in the market, held nearly 31% share in the global market in the same year.

    Comment?

  7. Soft Contact Lenses Market: Emerging Growth Factors and Forecasts 2027Read the original story w/Photo

    May 9, 2017 | PR-inside.com

    Transparency Market Research presents a new report on the global soft contact lenses market for the period 2017-2027. The report, titled "Soft Contact Lenses Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2027," looks into the market dynamics and growth trends to ascertain the growth curve of the said market.

    Comment?

  8. Valeant Pharmaceuticals Reports Tomorrow Morning, and This Is the Only Number That MattersRead the original story w/Photo

    May 8, 2017 | The Motley Fool

    Last year, Valeant wound up lowering its profit outlook and earnings before interest, taxes, depreciation, and amortization on three separate occasions, and some question whether the company's 2017 guidance wasn't a bit hopeful. Tomorrow, May 9, will see Valeant report its first-quarter earnings results before the opening bell, and who knows what to expect at this point.

    Comment?

  9. Global Femtosecond Lasers for Cataract Surgery Market 2017 - Alcon (Novartis), AbbottRead the original story w/Photo

    May 8, 2017 | SBWire

    The report headlined "Global Femtosecond Lasers for Cataract Surgery Market 2017"offers important insights into the global Femtosecond Lasers for Cataract Surgery market along with the updated industry data and industry upcoming trends, allowing you to point out the products and end users driving Revenue growth and profitability. Report Summary: The need of this vital research study on "Global Femtosecond Lasers for Cataract Surgery Market 2017" is to offer industry investors, company officials, and industry players with in-depth analysis to enable them make informed vital decisions related to the opportunities in the global Femtosecond Lasers for Cataract Surgery market.

    Comment?

  10. Global Implantable Drug Delivery Devices Market Will Increase CAGR by 7.1% Annually Till 2022Read the original story w/Photo

    Apr 28, 2017 | SBWire

    Zion Market Research has published a new report titled " Implantable Drug Delivery Devices Market for Oncology, Contraception, Cardiovascular, Ophthalmology, Inflammatory Conditions, Diabetes and Other End-users: Global Industry Perspective, Comprehensive Analysis, Size, Share, Growth, Segment, Trends and Forecast, 2015 - 2021." According to the report, global implantable drug delivery devices market was valued at around USD 11.6 billion in 2015 and is expected to generate revenue of around USD 17.5 billion by end of 2021, growing at a CAGR of around 7.1% between 2016 and 2021.

    Comment?

  11. Bausch & Lomb Receives 510(k) Clearance From FDA For Vitesse, the...Read the original story

    Apr 25, 2017 | BioSpace

    This new technology represents the first major vitreous removal innovation in 40 years, and one that will be available exclusively on the company's new Stellaris Elite "The successful clearance and upcoming launch of Vitesse is another opportunity in our 2017 launch plan, which we believe will provide truly innovative applications for retina surgeons and their patients," said Joseph C. Papa, Chairman and CEO of Valeant. "We look forward to bringing this next evolution, cutting-edge technology to market on our new Stellaris Elite platform."

    Comment?

  12. Valeant Pharmaceuticals Is An Asset Play And Any Growth Is A Margin Of SafetyRead the original story w/Photo

    Apr 24, 2017 | Seeking Alpha

    A simple examination of VRX's biggest assets reveals and highlights the current price of VRX as an asset play. A combination of the following will unlock shareholder value: demonstrating growth from the VRX pipeline, establishing a track record of meeting and beating earnings goals, or material asset sales.

    Comment?

  13. An Alcon Sale Will Take a Bargain PriceRead the original story w/Photo

    Apr 20, 2017 | Bloomberg

    Max Nisen is a Bloomberg Gadfly columnist covering biotech, pharma and health care. He previously wrote about management and corporate strategy for Quartz and Business Insider.

    Comment?

  14. pSivida To Report Third Quarter Fiscal Year 2017 Financial Results On Thursday, May 4thRead the original story

    Apr 19, 2017 | BioSpace

    The conference call may be accessed by dialing 312-7507 from the U.S. and Canada, or 813-4828 from international locations. The conference ID is 7711761.

    Comment?

  15. Research and Markets LogoRead the original story w/Photo

    Apr 19, 2017 | PR Newswire

    The surging acceptance of contact lens in sports activities and outdoor activities is expected to boost the market growth. The increasing acceptance of cosmetic contact lens by media and entertainment segment is further anticipated to bolster the market growth.

    Comment?

  16. A False Advertising Case Isn't Covered by "Personal and Advertising Injury" InsuranceRead the original story

    Apr 15, 2017 | ContractsProf Blog

    A recent case out of the Sixth Circuit, Vitamin Health, Inc. v. Hartford Casualty Insurance Co., No.

    Comment?

  17. Contact Lens Market: Cast Molding Emerges as Most Sought After Contact Lens Manufacturing TechnologyRead the original story w/Photo

    Apr 14, 2017 | SBWire

    The global market for contact lenses features a consolidated competitive landscape, with the top four companies, including Johnson & Johnson, The Cooper Companies, Alcona Inc. and Bausch and Lomb, accounting for a share of nearly 68% in the global market in 2015, states Transparency Market Research in a new report. Johnson & Johnson, the largest vendor in the market, held nearly 31% share in the global market in the same year.

    Comment?

  18. New Exhibit at Fairport MuseumRead the original story w/Photo

    Apr 13, 2017 | Genesee Valley Pennysaver

    ... and Rochester connection. Several items manufactured in Monroe County for the war effort are included: Bausch and Lomb binoculars, a communications device built by Stromberg Carlson, a compass made by Taylor Instruments and an ingenious trench ...

    Comment?

  19. Valeant Pharmaceuticals' Market Cap Is Now Lower Than Its Projected Full-Year EBITDARead the original story w/Photo

    Apr 13, 2017 | Fox News

    Recently, Valeant's stock broke lower through the $10-per-share price barrier, falling to a level investors haven't regularly seen since 2008. Its market cap of $3.3 billion now sits some 96% below where it was during the summer of 2015.

    Comment?

  20. Hartford wins false advertising coverage dispute with supplement makerRead the original story

    Apr 12, 2017 | Business Insurance

    A unit of Hartford Financial Services Inc. does not have to defend a policyholder against false advertising claims because the alleged disparagement of another company's products was by "implication," a federal appeals court ruled Tuesday. The case involved supplement manufacturer West Bloomfield, Michigan-based Vitamin Health Inc., which produced a supplement intended to reduce the risk of age-related macular degeneration, an eye disease causing vision loss.

    Comment?